Genotype-guided clopidogrel alone after heart stent in acute coronary syndrome
Tests single antiplatelet clopidogrel, guided by genotype, in adults with non-ST-elevation acute coronary syndrome.
Key facts
- Who runs it
- Sint Antonius Ziekenhuis Stichting
- Where
- Nieuwegein, NetherlandsSee the site
- Registry title
- POPular GUILTY PILOT: Genotype-guided Clopidogrel monotherapy
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 200 people, planned
- Started
- 15 Oct 2024
- Planned end
- 26 Jul 2026
- Type of study
- Interventional
- Record updated
- 29 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a heart attack or unstable angina (NSTE-ACS) who had a successful stent procedure (PCI) and have a certain CYP2C19 gene type.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- NSTE-ACS (NSTEMI or unstable angina) with a successful PCI, as judged by the treating doctor
- Earlier treatment
- People who already need dual antiplatelet therapy (DAPT) at admission cannot join. People taking oral blood thinners (anticoagulants) cannot join.
- Biomarker or test result
- CYP2C19 extensive or ultra-rapid metabolizer
Main reasons for not taking part
- CYP2C19 poor or intermediate metabolizer
- Planned surgery within 6 months of the PCI
- Pregnant or breastfeeding at enrolment
- Allergy or contraindication to aspirin or clopidogrel
- Recent stroke, TIA or bleeding inside the skull
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age 18 or older
- Clinical diagnosis of NSTE-ACS (i.e. NSTEMI or unstable angina)
- Successful PCI (according to the treating physician)
- CYP2C19 extensive or ultra-rapid metabolizer
Who cannot take part
- Planned surgical intervention within 6 months of PCI
- Participation in another trial with an investigational drug or device
- Concurrent use of oral anticoagulants (e.g. because of atrial fibrillation)
- Known allergy or contraindication for aspirin or clopidogrel
- High-risk features for PCI including left main disease, chronic total occlusion, bifurcation lesion requiring 2-stent treatment, saphenous or arterial graft lesion, severely calcified lesion requiring the use of the Rotablator system, ≥3 treated vessels, ≥ 3 stents implanted and total stent length >60 mm
- Recent stroke, transient ischemic attack (TIA) or intracranial bleeding
- Severe hepatic impairment (Child Pugh class C)
- CYP2C19 poor or intermediate metabolizer
- Pregnant or breastfeeding women at time of enrolment
- Ongoing indication for DAPT at admission (e.g. due to recent PCI or ACS)
Where in Netherlands
- Sint Antonius Ziekenhuis StichtingNieuwegein, NetherlandsTaking people
About the trial
What the trial wants to find out
1. To assess ischemic risk (i.e. efficacy) of genotype-guided clopidogrel monotherapy during the first 6 months following successful PCI in NSTE-ACS patients. 2. To assess bleeding risk (i.e. safety) of genotype-guided clopidogrel monotherapy during the first 6 months following successful PCI in NSTE-ACS patients.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- POPular GUILTY PILOT: Genotype-guided Clopidogrel monotherapy
- Plain-language title
- Genotype-guided clopidogrel alone after heart stent in acute coronary syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 29 January 2026